# A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

> **NCT06330064** · PHASE2 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 520 (estimated)

## Conditions studied

- Recurrent or Metastatic Solid Tumors

## Interventions

- **DRUG:** Ifinatamab deruxtecan

## Key facts

- **NCT ID:** NCT06330064
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2028-07-25
- **Final completion:** 2028-07-25
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06330064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06330064, "A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06330064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*